Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+CD16-CD56- large granular lymphocyte LAK cells
Open Access
- 1 November 1990
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 82 (2) , 416-421
- https://doi.org/10.1111/j.1365-2249.1990.tb05463.x
Abstract
It has been reported that lymphocytes from peripheral blood (PBL) cultured with interleukin-2 (IL-2) produce predominantly CD16+ lymphokine-activated killer (LAK) cells. We developed a two-step method to generate LAK cells from human PBL in long-term cultures (10–12 days) with recombinant human IL-2 (rhIL-2) and characterized the evolving LAK cell population by testing its phenotype and cytotoxic activity as a function of time. The starting PBL displayed some natural killer (NK) cytotoxicity but no LAK activity. At day 6, the cells were a mixed population of about 80% CD3+ and 6% CD16+ cells. Little proliferation was evident but strong LAK activity was detected. After 10–12 days, major cell expansion had occurred and they were essentially a pure (>90%) CD3+CD16-CD56- cell population large granular lymphocyte (LGL) by morphology that displayed strong non-MHC-restricted killing activity (> 200 lytic units). Over the same period of time, the CD16+ cells had almost completely regressed in these cultures. This preferential induction of CD+ LAK cells was not an effect of IL-2 concentration as 10 U/ml was as effective as 500 U/ml. Further characterization revealed a major population of CD4+ (60%) and CD8+ (30%) with a smaller fraction (+ cells. These results indicate that a virtually pure CD3+ LAK cells population was produced with long-term cultures of lymphocytes from peripheral blood in rhIL-2, in which active proliferation of the CD3+ but not CD16+ cells occurred.Keywords
This publication has 25 references indexed in Scilit:
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- Lymphokine-activated killer cells. Analysis of progenitors and effectors.The Journal of Experimental Medicine, 1986
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Change in functional phenotype of cloned human alloreactive cytolytic T cellsHuman Immunology, 1984
- Response of resting human peripheral blood natural killer cells to interleukin 2.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Phenotypic and functional heterogeneity of human cloned natural killer cell linesNature, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- surface markers of mono‐and multi‐functional mixed leukocyte culture‐derived T cell clones in manEuropean Journal of Immunology, 1982